Amgen launches AMGEVITATM (Biosimilar Adalimumab) In markets across Europe

Amgen (NASDAQ:AMGN) announced that AMGEVITATM, a biosimilar to adalimumab, will launch in markets across Europe beginning on Oct. 16, 2018. AMGEVITA is the first adalimumab biosimilar to be approved by the European Commission (EC). AMGEVITA is authorized for the treatment of

Source: World Pharma News - October 17, 2018 Category: Pharmaceuticals Tags: Featured Amgen Business and Industry Source Type: news